Patient P-02363
Synthetic patientMETA-24 · Day 168 · 35–44 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
71%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 70 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 78 GI-04 recommended — GI Support Protocol GI-04
- Day 79 Patient accepted — Started GI-04 in the companion
- Day 86 ME-01 recommended — Monitoring Escalation ME-01
- Day 87 GI symptom burden −19% vs expected — GI Support Protocol GI-04
- Day 87 Patient accepted — Started ME-01 in the companion
- Day 90 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 93 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 70.
Primary contributors, last 14 days
- GI instability-10
- Treatment adherence-8
- Nutritional resilience+5
- Toxicity+5
- Inflammatory activity-2
What helped?
- GI Support Protocol GI-04Day 78Result: symptom burden −19%
- Monitoring Escalation ME-01Day 86Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable44 min
worsening · -3.6 vs previous 14 d
Sleep duration
Wearable5.2 h
worsening · -0.3 vs previous 14 d
Energy level
Daily log2.4/10
worsening · -0.3 vs previous 14 d
Steps
Wearable4,964
worsening · -331 vs previous 14 d
GI burden
Companion51.2/100
worsening · +5.1 vs previous 14 d
Adherence
Companion44.4 %
worsening · -4.0 vs previous 14 d
Sleep quality
Wearable19.5/100
worsening · -5.9 vs previous 14 d
Glucose, CGM daily mean
CGM142 mg/dL
stable · +2.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 33 from the failing basin, 55 from restoration.
Would help
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 71%
- SC-12 Supportive Compound69% improved among 26 similar · onset 6 d · confidence 71%
- CR-01 Clinician Review100% improved among 6 similar · onset 5 d · confidence 71%
- More proteinGI -6.2 next day on high-intake days · n 22
Would not help
- Keep fat lowGI +6.7 next day on high-intake days · n 20
- Keep simple carbs lowGI +5.5 next day on high-intake days · n 22
- Keep histamine lowGI +5.4 next day on high-intake days · n 22
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+6.7detractor · 95%
- Protein-6.2supporter · 95%
- Simple carbohydrates+5.5detractor · 95%
- Histamine load+5.4detractor · 95%
- Ultra-processed food+4.9detractor · 95%
- Alcohol+3.9detractor · 93%
- Caffeine+0.5no signal · 15%
- Insoluble fibre-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 51 and rising
- WearableSleep 5.2 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 56
- WearableHRV 31 ms, trending down
- Autonomic recovery ↑45
- WearableResting HR 74 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 55
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.5 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 28 ms
- Sleep
- 5.3 h
- Steps
- 4,804
- Resting HR
- 77 bpm
Daily log: GI score 51, nutritional resilience 43, adherence 44.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02118 | 58% | S14 | GI-04 | improved | 47 |
| P-02535 | 57% | S14 | SC-12 | improved | 50 |
| P-02574 | 57% | S14 | ME-01 | improved | 45 |
| P-02633 | 56% | S14 | NP-02 | improved | 48 |
| P-02002 | 53% | S14 | GI-04 | improved | 47 |
| P-02125 | 53% | S14 | GI-04 | improved | 55 |
| P-02348 | 52% | S14 | GI-04 | improved | 49 |
| P-02670 | 52% | S14 | SC-12 | improved | 45 |
| P-02253 | 50% | S14 | NP-02 | no change | 41 |
| P-02268 | 50% | S14 | GI-04 | improved | 43 |
| P-02320 | 50% | S14 | NP-02 | improved | 50 |
| P-02648 | 50% | S14 | SC-12 | improved | 47 |